Graham Capital Management’s C4 Therapeutics CCCC Stock Holding History

Graham Capital Management’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-23,733	Closed	-$62.4K	–	1282
2026 Q1	$62.4K	Sell	23,733 -78,465	-77%	-$185K	﹤0.01%	1078
2025 Q4	$195K	Buy	102,198 +61,570	+152%	+$146K	﹤0.01%	1050
2025 Q3	$90.2K	Buy	+40,628	New	+$97.5K	﹤0.01%	1163
2024 Q2	–	Sell	-47,449	Closed	-$388K	–	1070
2024 Q1	$388K	Buy	+47,449	New	+$368K	0.01%	692
2023 Q3	–	Sell	-32,974	Closed	-$90.7K	–	1037
2023 Q2	$90.7K	Buy	+32,974	New	+$106K	﹤0.01%	896

Other funds holding CCCC

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Graham Capital Management's CCCC Position: Q2 2026 in Review

Graham Capital Management sold out of C4 Therapeutics (CCCC) in Q2 2026, closing a stake of 23,733 shares — an estimated $62.4K sold.

Graham Capital Management first reported a position in CCCC in Q2 2023 and held it in 5 quarters. The position peaked at $388K in Q1 2024. 147 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

Graham Capital Management reported no remaining C4 Therapeutics position as of Q2 2026 after selling out during the quarter.
Graham Capital Management sold 23,733 C4 Therapeutics shares in Q2 2026, an estimated $62.4K.
Graham Capital Management first reported a position in C4 Therapeutics in Q2 2023 and held it in 5 quarters.
Graham Capital Management's C4 Therapeutics position peaked at $388K in Q1 2024.
147 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.